Skip to main content

Table 4 Secondary efficacy measures

From: Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory posttraumatic stress disorder

Combined suppression of nightmares and intrusions
Responder status, n (%)  
   Full 26/33 (79%)
   Partial 3/33 (9%)
   None 4/33 (12%)
Mean time to response, days ± SD, (range)  
   Full response (n = 25) 15 ± 18 (1–83)
   Partial response (n = 17) 11 ± 13 (2–46)
Median time to full response, days 9
Median time to partial response, days 5
Mean dosage at time of response, mg/day  
   Full response 60 ± 47
   Partial response 32 ± 15
Median dosage at time of response, mg/day  
   Full response 50
   Partial response 25
Modal daily dosage for full response, mg/day 25
   % of patients in the 12.5–50-mg/day range 65
Modal dosage at time of partial response, mg/day 25
   % of patients in the 12.5–50-mg/day range 100
Improvements in nightmares  
Full cessation of nightmares 17/18 (94%)
Improvements in intrusions  
Full cessation of intrusions 26/33 (79%)
Partial improvement 3/33 (9%)
No improvement 4/33 (12%)
  1. SD = standard deviation.